Old Web
English
Sign In
Acemap
>
authorDetail
>
H Lanz
H Lanz
Daiichi Sankyo
Atrial fibrillation
Medicine
Cardiology
TIMI
in patient
3
Papers
0
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Serial measurement of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in ENGAGE AF-TIMI 48
2020
European Heart Journal
Kazuma Oyama
Robert P. Giugliano
David D. Berg
Christian T. Ruff
Minao Tang
Sabina A. Murphy
H Lanz
Michael A. Grosso
Elliot M Antman
E. Braunwald
David A. Morrow
Show All
Source
Cite
Save
Citations (0)
Periprocedural anticoagulation in the uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation (ELIMINATE-AF) trial.
2020
Europace
Stefan H. Hohnloser
A. John Camm
Riccardo Cappato
Hans Christoph Diener
Hein Heidbuchel
Lluis Mont
Carlos A. Morillo
H Lanz
Heiko Rauer
Paul-Egbert Reimitz
Rüdiger Smolnik
Josef Kautzner
Show All
Source
Cite
Save
Citations (0)
P3586Efficacy and safety of edoxaban vs. warfarin in patients with atrial fibrillation and hepatic disease: Insights from the ENGAGE AF-TIMI 48 trial
2017
European Heart Journal
Arman Qamar
Elliott A Antman
Christian T. Ruff
Sabina A. Murphy
Francesco Nordio
Youngsook Choi
H Lanz
Michele Mercuri
E. Braunwald
Robert P. Giugliano
Show All
Source
Cite
Save
Citations (0)
1